Paid Clinical Trials Gulfport
Discover 44 paid clinical trials in Gulfport, Mississippi. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Investigational CMV Vaccine Study for Volunteers Ages 9–15Investigational CMV Vaccine Study for Volunteers Ages 9–15
Sponsor:
Moderna
Location:
Code:
NCT05575492
Conditions
Cytomegalovirus
Eligibility Criteria
Sex: All
Age: 9 - 15
Healthy Volunteers: Accepted
Interventions
mRNA-1647
Placebo
A Study of GEn-1124 in Subjects with Acute Respiratory Distress Syndrome (ARDS)A Study of GEn-1124 in Subjects with Acute Respiratory Distress Syndrome (ARDS)
Sponsor:
GEn1E Lifesciences
Location:
Code:
NCT05795465
Conditions
Respiratory Distress Syndrome, Acute
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
GEn-1124
Placebo
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary DiseaseA Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Sponsor:
AstraZeneca
Location:
Code:
NCT06283966
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Eligibility Criteria
Sex: All
Age: 40 - 70+
Healthy Volunteers: Not accepted
Interventions
BGF MDI 320/14.4/9.6 μg
GFF MDI 14.4/9.6 μg
A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary FibrosisA Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
Sponsor:
Boehringer Ingelheim
Location:
Code:
NCT06360094
Conditions
Idiopathic Pulmonary Fibrosis
Progressive Pulmonary Fibrosis
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
BI 1839100
Placebo
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and InflammationA Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
Sponsor:
Novo Nordisk A/S
Location:
Code:
NCT05636176
Conditions
Heart Failure
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Ziltivekimab
Placebo
A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
Sponsor:
Melt Pharmaceuticals
Location:
Code:
NCT06383273
Conditions
Cataract
Eligibility Criteria
Sex: All
Age: 18 - 65
Healthy Volunteers: Not accepted
Interventions
MELT-300 sublingual tablet
Midalozam sublingual tablet
Placebo sublingual tablet
MILD® Percutaneous Image-Guided Lumbar Decompression: a Medicare Claims StudyMILD® Percutaneous Image-Guided Lumbar Decompression: a Medicare Claims Study
Sponsor:
Vertos Medical, Inc.
Location:
Code:
NCT03072927
Conditions
Lumbar Spinal Stenosis
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
MILD
Interspinous Process Decompression
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related ComorbiditiesA Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
Sponsor:
Eli Lilly and Company
Location:
Code:
NCT06672939
Conditions
Obesity
Overweight
Eligibility Criteria
Sex: All
Age: 12 - 17
Healthy Volunteers: Not accepted
Interventions
Orforglipron
Placebo
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy DurationS1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
Sponsor:
SWOG Cancer Research Network
Location:
Code:
NCT04071457
Conditions
Multiple Myeloma
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Lenalidomide
Daratumumab/rHuPH20
Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck CancerComparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer
Sponsor:
NRG Oncology
Location:
Code:
NCT05050162
Conditions
Advanced Head and Neck Squamous Cell Carcinoma
Advanced Hypopharyngeal Squamous Cell Carcinoma
Advanced Laryngeal Squamous Cell Carcinoma
Advanced Oropharyngeal Squamous Cell Carcinoma
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Cisplatin
Computed Tomography
Magnetic Resonance Imaging
Positron Emission Tomography
Quality-of-Life Assessment
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef ExtensionOpen-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT06492291
Conditions
Hypercholesterolemia
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Enlicitide Decanoate